SG11201901251SA - Aminopyrimidines as alk inhibitors - Google Patents
Aminopyrimidines as alk inhibitorsInfo
- Publication number
- SG11201901251SA SG11201901251SA SG11201901251SA SG11201901251SA SG11201901251SA SG 11201901251S A SG11201901251S A SG 11201901251SA SG 11201901251S A SG11201901251S A SG 11201901251SA SG 11201901251S A SG11201901251S A SG 11201901251SA SG 11201901251S A SG11201901251S A SG 11201901251SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- co7d
- english
- august
- Prior art date
Links
- 150000005005 aminopyrimidines Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000013350 formula milk Nutrition 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000012546 transfer Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380818P | 2016-08-29 | 2016-08-29 | |
| PCT/US2017/048845 WO2018044767A2 (en) | 2016-08-29 | 2017-08-28 | Aminopyrimidines as alk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901251SA true SG11201901251SA (en) | 2019-03-28 |
Family
ID=59846649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901251SA SG11201901251SA (en) | 2016-08-29 | 2017-08-28 | Aminopyrimidines as alk inhibitors |
| SG10201914030UA SG10201914030UA (en) | 2016-08-29 | 2017-08-28 | Aminopyrimidines as alk inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201914030UA SG10201914030UA (en) | 2016-08-29 | 2017-08-28 | Aminopyrimidines as alk inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10709705B2 (OSRAM) |
| EP (2) | EP4001273A3 (OSRAM) |
| JP (2) | JP7094566B2 (OSRAM) |
| KR (1) | KR102530871B1 (OSRAM) |
| CN (2) | CN115043821B (OSRAM) |
| AU (2) | AU2017319135B2 (OSRAM) |
| IL (1) | IL264638B (OSRAM) |
| MX (2) | MX389265B (OSRAM) |
| NZ (1) | NZ751713A (OSRAM) |
| SG (2) | SG11201901251SA (OSRAM) |
| WO (1) | WO2018044767A2 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110772638B (zh) * | 2018-07-31 | 2021-02-23 | 苏州亚盛药业有限公司 | Alk抑制剂与egfr抑制剂在制备治疗癌症的药物中的用途 |
| CN111171033B (zh) * | 2018-11-09 | 2021-11-02 | 天津大学 | 一种嘧啶衍生物及其合成方法和应用 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN110143947B (zh) * | 2019-05-29 | 2021-10-15 | 华东师范大学 | 一种色瑞替尼类似物的制备方法 |
| WO2020259553A1 (en) * | 2019-06-25 | 2020-12-30 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of fak inhibitor and btk inhibitor for treating a disease |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022063220A1 (en) * | 2020-09-25 | 2022-03-31 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical composition and use thereof for treatment of cancer |
| US20240316051A1 (en) * | 2021-04-19 | 2024-09-26 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical combination and use thereof |
| EP4446320A4 (en) * | 2021-12-09 | 2025-11-26 | Oncobix Co Ltd | NEW HETEROCYCLIC SUBSTITUTION PYRIMIDINE DERIVATIVE WITH CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING IT |
| CN116332919B (zh) * | 2022-03-30 | 2025-08-26 | 苏州亚盛药业有限公司 | 一种alk抑制剂化合物及其中间体的制备方法 |
| TWI885708B (zh) * | 2023-01-20 | 2025-06-01 | 大陸商蘇州亞盛藥業有限公司 | Alk抑制劑或其鹽、溶劑合物的結晶形式及其製備方法和應用 |
| JP2026511009A (ja) * | 2023-03-22 | 2026-04-10 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | 医薬組合せ及びその使用 |
| WO2025232723A1 (en) * | 2024-05-06 | 2025-11-13 | Ascentage Pharma (Suzhou) Co., Ltd. | Treatment method with focal adhesion kinase inhibitor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| TWI378923B (en) | 2003-08-15 | 2012-12-11 | Novartis Ag | Pyrimidine derivatives |
| BRPI0414544A (pt) * | 2003-09-18 | 2006-11-07 | Novartis Ag | 2,4-di-(fenilamino) pirimidinas úteis no tratamento de transtornos proliferativos |
| RS52545B (sr) * | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
| BRPI0722383A2 (pt) | 2006-12-08 | 2012-06-05 | Irm Llc | compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos |
| US8592432B2 (en) | 2008-04-07 | 2013-11-26 | Bei Chen | Compounds and compositions as protein kinase inhibitors |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| US20140024620A1 (en) | 2010-10-14 | 2014-01-23 | Ariad Pharmaceuticals, Inc. | Methods for Inhibiting Cell Proliferation in EGFR-Driven Cancers |
| HUE025395T2 (en) | 2011-02-02 | 2016-02-29 | Novartis Ag | Methods using ALK inhibitors |
| CN104672214B (zh) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
-
2017
- 2017-08-28 SG SG11201901251SA patent/SG11201901251SA/en unknown
- 2017-08-28 WO PCT/US2017/048845 patent/WO2018044767A2/en not_active Ceased
- 2017-08-28 KR KR1020197007075A patent/KR102530871B1/ko active Active
- 2017-08-28 EP EP21212760.9A patent/EP4001273A3/en not_active Withdrawn
- 2017-08-28 US US15/559,445 patent/US10709705B2/en active Active
- 2017-08-28 SG SG10201914030UA patent/SG10201914030UA/en unknown
- 2017-08-28 NZ NZ751713A patent/NZ751713A/en unknown
- 2017-08-28 JP JP2019511664A patent/JP7094566B2/ja active Active
- 2017-08-28 MX MX2019002393A patent/MX389265B/es unknown
- 2017-08-28 EP EP17764949.8A patent/EP3504203B1/en active Active
- 2017-08-28 CN CN202210533398.XA patent/CN115043821B/zh active Active
- 2017-08-28 CN CN201780057518.0A patent/CN109715620B/zh active Active
- 2017-08-28 AU AU2017319135A patent/AU2017319135B2/en active Active
-
2019
- 2019-02-04 IL IL264638A patent/IL264638B/en unknown
- 2019-02-27 MX MX2022000376A patent/MX2022000376A/es unknown
-
2020
- 2020-06-29 US US16/914,518 patent/US11110090B2/en active Active
-
2021
- 2021-05-14 AU AU2021203098A patent/AU2021203098B2/en active Active
-
2022
- 2022-06-15 JP JP2022096630A patent/JP2022120151A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102530871B1 (ko) | 2023-05-09 |
| WO2018044767A2 (en) | 2018-03-08 |
| US20190175595A1 (en) | 2019-06-13 |
| KR20190039760A (ko) | 2019-04-15 |
| MX2022000376A (es) | 2022-02-10 |
| AU2017319135A1 (en) | 2019-04-04 |
| US11110090B2 (en) | 2021-09-07 |
| AU2017319135B2 (en) | 2021-03-18 |
| EP4001273A2 (en) | 2022-05-25 |
| US10709705B2 (en) | 2020-07-14 |
| SG10201914030UA (en) | 2020-03-30 |
| MX389265B (es) | 2025-03-20 |
| WO2018044767A3 (en) | 2018-04-12 |
| AU2021203098A1 (en) | 2021-06-10 |
| BR112019003897A2 (pt) | 2019-05-21 |
| JP2019528307A (ja) | 2019-10-10 |
| AU2021203098B2 (en) | 2023-05-25 |
| MX2019002393A (es) | 2019-07-08 |
| CN109715620B (zh) | 2022-05-06 |
| EP3504203B1 (en) | 2022-09-28 |
| EP4001273A3 (en) | 2022-08-24 |
| NZ751713A (en) | 2022-07-01 |
| JP7094566B2 (ja) | 2022-07-04 |
| CA3033223A1 (en) | 2018-03-08 |
| EP3504203A2 (en) | 2019-07-03 |
| CN115043821A (zh) | 2022-09-13 |
| CN115043821B (zh) | 2024-08-06 |
| JP2022120151A (ja) | 2022-08-17 |
| US20200330464A1 (en) | 2020-10-22 |
| IL264638B (en) | 2021-08-31 |
| CN109715620A (zh) | 2019-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201908542QA (en) | Gip receptor activating peptide | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201909083UA (en) | Piperidines as covalent menin inhibitors | |
| SG11201909710XA (en) | Indole ahr inhibitors and uses thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201907744QA (en) | Replacement of cytotoxic preconditioning before cellular immunotherapy | |
| SG11201909825VA (en) | Hsp90 inhibitor oral formulations and related methods | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201901658PA (en) | Beta-lactamase inhibitor compounds | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201907023UA (en) | Method of reducing neutropenia |